Pure Global
NCT05781425

Prediction of Getting Peripheral Neuropathy in Patients Treated With Bortezomib?

Neurofilament Light Chain as Biomarker for Bortezomib-induced Peripheral Neuropathy
Odense University Hospital·ClinicalTrials.govNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Chemotherapy-induced Peripheral Neuropathy
Study type
Observational
Sponsor & location
Primary sponsor
Odense University Hospital
Timeline & enrollment
Phase
N/A
Start date
Apr 01, 2023
End date
Dec 31, 2023
Enrollment
20 participants
Primary outcome

Level of plasma neurofilament light chain,Level of plasma neurofilament light chain,Level of plasma neurofilament light chain,Level of plasma neurofilament light chain,Level of plasma neurofilament light chain,Level of plasma neurofilament light chain,Level of plasma neurofilament light chain,Level of plasma neurofilament light chain,Level of plasma neurofilament light chain,Level of plasma neurofilament light chain

Summary

Investigation of which patients treated with bortezomib that have increased risk of
 developing peripheral neuropathy.

ICD-10 classifications
Drug-induced polyneuropathyParaneoplastic neuromyopathy and neuropathyPolyneuropathy due to other toxic agentsIdiopathic peripheral autonomic neuropathyIdiopathic progressive neuropathy
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05781425
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05781425 through Pure Global AI's free database. This phase not specified trial is sponsored by Odense University Hospital and is currently Not yet recruiting. The study focuses on Chemotherapy-induced Peripheral Neuropathy. Target enrollment is 20 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.